PECAM1 and arthritic joint disease: In the adjuvant-induced arthritis model, mPEG-SC20K-HM-3 (PEG-HM-3) treatment decreased the levels of IL-6 in spleens, TNF-α, cluster of differentiation 31 (CD31) and CD105 in the joint cavity by immunohistochemistry analysis [10].